Home > Riviste > Minerva Cardiology and Angiology > Fascicoli precedenti > Articles online first > Minerva Cardiology and Angiology 2021 Oct 29

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Cardiology and Angiology 2021 Oct 29

DOI: 10.23736/S2724-5683.21.05794-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Reverse remodelling in diabetic cardiomyopathy: the role of extracellular matrix

Ibrahim AYKAC, Bruno K. PODESSER, Attila KISS

Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Vienna, Austria


PDF


Diabetic patients are prone to suffer from cardiovascular disease, specifically from ischemic heart disease and diabetic cardiomyopathy, which have a huge impact on morbidity and mortality worldwide. Cardiac fibrosis due to alteration of the extracellular matrix (ECM) remodelling is often observed in diabetes and myocardial fibrosis is an important part of cardiac remodeling that leads to heart failure and death. At single-cell level, the ECM govern, metabolism, motility, orientation and proliferation. However, in pathological condition such as diabetes, changes in ECM lead to fibrosis and subsequently cardiac stiffness and cardiomyocytes dysfunction. Anti-diabetic drugs, particularly sodium-glucose cotransporter-2 (SGLT2) inhibitors have anti-fibrotic effects, and may promote ECM reverse remodelling. In this mini-review, the mechanisms and the role of ECM remodelling and reverse remodelling as a potential therapeutic targets for diabetic cardiomyopathy are discussed.


KEY WORDS: Diabetes; Extracellular matrix; Reverse remodelling; Fibrosis

inizio pagina